http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Yuki Mori ),( Fumihiko Iwamoto ),( Yasuaki Ishida ),( Toru Kuno ),( Shoji Kobayashi ),( Takashi Yoshida ),( Tatsuya Yamaguchi ),( Tadashi Sato ),( Makoto Sudo ),( Daisuke Ichikawa ),( Nobuyuki Enomo 대한장연구학회 2020 Intestinal Research Vol.18 No.4
Behçet’s disease (BD) is a multisystem inflammatory disease of unknown origin. Rarely, BD occurs together with myelodysplastic syndrome (MDS). Interestingly, it is speculated that these are not simple coexistence but that the etiology of intestinal BD is at least partly derived from MDS itself. Furthermore, there is a relationship between MDS in patients with intestinal BD and trisomy 8. Immunosuppressive agents alone are insufficient to control MDS-associated BD, and many of these patients die of infection or hemorrhage. Surgery is considered for intestinal BD patients who are unresponsive to medical treatment or those with bowel complications such as perforation or persistent bleeding. We report a case of intestinal BD associated with MDS and trisomy 8. The patient was unresponsive to oral steroids and immunosuppressive treatment; the patient improved by surgical repair of a bowel perforation. Five years after the surgery, the patient is free of recurrence and not on medication. Our experience suggests that surgery may provide an effective therapeutic option for the treatment of MDS-related BD. (Intest Res 2020;18:469-475)
( Yuki Wada ),( Hideyuki Tamai ),( Akira Kawashima ),( Naoki Shingaki ),( Yoshiyuki Mori ),( Masanori Kawaguchi ),( Kosaku Moribata ),( Hisanobu Deguchi ),( Kazuki Ueda ),( Izumi Inoue ),( Takao Maeki 대한소화기학회 2014 Gut and Liver Vol.8 No.4
Background/Aims: The present study aimed to clarify whether virological response within 2 weeks after therapy initiation can predict a null response to pegylated interferon α-2b plus ribavirin therapy in patients with high viral load genotype 1b hepatitis C. Methods: The participants consisted of 72 patients with high viral load genotype 1b. The dynamics of viral load within 2 weeks were measured. Results: Significant differences between null responders and nonnull responders were noted for interleukin (IL)-28B genotype, amino acid 70 substitution, α-fetoprotein, low-density lipoprotein cholesterol, hyaluronic acid, and viral response. The area under the curve (AUC) for the receiver operating characteristic curve of the hepatitis C virus (HCV) RNA level decline at 2 weeks (AUC=0.993) was the highest among the factors predicting the null response. When the cutoff value for the HCV RNA level decline at 2 weeks was set at 0.80 log, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy in predicting a null response were 82%, 96%, 82%, 96%, and 94%, respectively. In comparison, values for the non-TT and mutant type of amino acid 70 substitution were similar to those for HCV RNA level decline at 2 weeks. Conclusions: Virological response at 2 weeks or the combination of IL-28B and amino acid 70 substitution are accurate predictors of a null response. (Gut Liver 2014;8:421-427)
National Health and Aging Policy Program in Brazil: Considerations for the Future
Douglas Mori,Yuki Sawada,Hiroshi Sumii,Akemi Karia,Satoshi Imaizumi 한국노인복지학회 2011 International Journal of Welfare for the Aged Vol.25 No.-
Recently, the notable increase in longevity and decrease in birthrate have changed the demographic profile of Brazilian people. Good health requires harmony coexistence condition expression between Health Care System and the Brazilian Society. In order to provide good quality of life to their citizens, the state and Federal governments of Brazil have shown some concerns for the elderly health care and are setting up some public programs and policies to provide Social Security and Health Care Programs for the elderly. These programs and policies are called the Elderly Statute and the National Health Policy for the Elderly Person. The aim of this study is to to review the scientific literature on these programs/policies and examine the government actions that will directly affect the health care of the elderly.
Mitsukuri, Yuki,Hara, Ryoichi,Kita, Hiroyuki,Watanabe, Keiichi,Mori, Kenjiro,Kataoka, Yasuhiro,Kogure, Eiji,Mishima, Yuji The Korean Institute of Electrical Engineers 2014 The Journal of International Council on Electrical Vol.4 No.2
A surge of needs for the low carbon society promotes a spread of electric vehicle (EV). EVs could be charged at night simultaneously, as a result, severe voltage drop may happen. The authors have proposed the method which can compensate the voltage drop caused by EV charging by means of adjusting charging schedules and controlling reactive power. And, we have confirmed the effectiveness of the method by estimating steady state in order to figure out the limitation of the control capability. In this paper, from a practical viewpoint, we propose the method to consider dynamic behavior. In this method, the EV can not only finish charging effectively but also control minimal reactive power to keep admissible voltage with monitoring system voltage.
Abe, Hajime,Mori, Tsuyoshi,Kawai, Yuki,Tomida, Kaori,Kubota, Yoshihiro,Umeda, Tomoko,Tani, Tohru Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.8
Background: We compared treatment completion rates and safety of docetaxel and cyclophosphamide sixcycle therapy (TC6) with docetaxel followed by 5FU, epirubicin and cyclophosphamide (T-FEC) therapy in Japanese patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Materials and Methods: We administered TC6 q3w or T-FEC q3w to HER2-negative breast cancer patients. The primary endpoint of this trial was toxicity. As second endpoints, the treatment completion rate and relative dose intensity were evaluated. Results: The TC6 and T-FEC group consisted of 22 and 21 patients, respectively. Concerning hematological toxicity, grade 3 or higher adverse reactions included neutropenia and febrile neutropenia. As non-hematological adverse events, exanthema and peripheral neuropathy were frequently reported in the TC6 group, whereas more patients of the T-FEC group reported nausea and vomiting. In TC6, the treatment completion rate was 86.4% and the relative dose intensity of docetaxel was 93.2%. In T-FEC, the values were 95.2% and 98.9%, respectively. Conclusions: These results suggest that TC6 is tolerable in Japanese, and that this regimen can also be performed in outpatient clinics. However, with the TC6 regimen, the compliance was slightly lower than with the T-FEC regimen, and supportive therapy needs to be managed appropriately.
Vehicle Braking Control Using Sliding Mode Control
Misawa Kasahara,Yuki Kanai,Yasuchika Mori 제어로봇시스템학회 2009 제어로봇시스템학회 국제학술대회 논문집 Vol.2009 No.8
In recent years, anti-lock brake system and brake-by-wire are proposed in the vehicle control using a brake, and the braking power is expected to be improved more than ever. The researches such as an application to the ABS of Siliding mode control which considered a actuator dynamics [1] and a hybrid control of the brake using model reference adaptive control [2] are done so far. However, in the former case, speed following that be comes a target exists physically impossible situation by saturation of tire frictional force because only speed following is one. In the latter, the model error is caused because the simulation model and the controller design model are different. There fore, there is a problem that an accurate follow can not be done. In this paper, the braking control is performed using the sliding mode control [3] which has high robustness for disturbance that fulfils matching conditions. In so doing, it aims attheachievement of optimal braking control to switch wheel speed following to slip rati o following.
Abe, Hajime,Mori, Tsuyoshi,Kawai, Yuki,Tomida, Kaori,Yamazaki, Keiichi,Kubota, Yoshihiro,Umeda, Tomoko,Tani, Tohru Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.8
Background: The infusion rate is considered to affect incidence and severity of infusion reactions (IRs) caused by protein formulations. Trastuzumab (TRS) is approved for 90-minute infusion as the initial dose followed by 30-minute infusion with 250 ml saline. In the study, we evaluated the safety of TRS intravenously administered over 30 minutes with 100 ml saline to reduce burden of patients, safety of infusion with 250 ml saline already being established. Materials and Methods: Women with HER2 positive breast cancer, ${\geq}18$ years and ${\geq}55%$ left ventricular ejection fraction (LVEF), were registered in the study. Patients received 8mg/kg of TRS 250 ml over 90 minutes followed by 6mg/kg of TRS 100ml over 30 minutes in a three-week cycle. Results: A total of 31 patients were recruited, 24 for adjuvant therapy and seven with metastases. The median age was 59 years (range 39 to 82). The total number of TRS doses ranged from 5 to 17 with the median of 15. Mild IR occurred in two patients at the first dose. However, no IR was observed after reducing to 100 ml saline. No decrease of LVEF, increase of serum brain natriuretic peptide or any other adverse events were reported. Conclusions: Intravenous infusion of TRS with 100 ml saline over 30 minutes in breast cancer patients can be considered safe based on results from the study. It can be given on an outpatient basis as with the currently recommended dilution in 250 ml saline.
Abe, Hajime,Kawai, Yuki,Mori, Tsuyoshi,Tomida, Kaori,Kubota, Yoshihiro,Umeda, Tomoko,Tani, Tohru Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.11
Background: Goshajinkigan (GJG) is used for the treatment of several neurological symptoms. We investigated the efficacy of GJG and mecobalamin (B12) against neurotoxicity associated with docetaxel (DOC) in breast cancer patients. Materials and Methods: Sixty breast cancer patients were treated with DOC. Thirty-three patients (GJG group) received oral administration of 7.5 g/day GJG and 27 patients (B12 group) received oral administration of 1500 ${\mu}g/day$ B12. Neuropathy was evaluated according to DEB-NTC (Neurotoxicity Criteria of Debiopharm), Common Terminology Criteria for Adverse Events (NCI-CTC) ver. 3.0, and a visual analogue scale (VAS). This study employed a randomized open design. Results: The incidence of neuropathy was 39.3% in the GJG group, and 88.9% in the B12 group (p<0.01). In the GJG group, grade 1 DEB-NTC was observed in 2 cases, grade 2 in 5 cases and grade 3 in 5 cases. Grade 1 NCI-CTC was observed in 7 cases, grade 2 in 6 cases, and VAS was $2.7{\pm}2.2$. In the B12 group, grades 1, 2 and 3 DEB-NTC were observed in one case, 12 cases and 12 cases, respectively; and grades 1, 2 and 3 NCI-CTC were observed in 11 cases, 12 cases and one case, and VAS was $4.9{\pm}2.4$. Conclusions: Concomitant administration of GJG is useful in preventing neuropathy in breast cancer patients treated with a DOC regimen.
Clinical Efficacy of Endocytoscopy for Gastrointestinal Endoscopy
Masashi Misawa,Shin-ei Kudo,Yuki Takashina,Yoshika Akimoto,Yasuharu Maeda,Yuichi Mori,Toyoki Kudo,Kunihiko Wakamura,Hideyuki Miyachi,Fumio Ishida,Haruhiro Inoue 대한소화기내시경학회 2021 Clinical Endoscopy Vol.54 No.4
Endocytoscopy (EC) is a contact-type optical endoscope that allows in vivo cellular observation during gastrointestinal endoscopyand is now commercially available not only in Japan but also in Asian, European Union, and Middle Eastern countries. EC helpsconduct a highly accurate pathological prediction without biopsy. Initially, EC was reported to be effective for esophageal diseases. Subsequently, its efficacy for stomach and colorectal diseases has been reported. In this narrative review, we searched for clinicalstudies that investigated the efficacy of EC. EC seems to accurately diagnose gastrointestinal diseases without biopsy. Most of thestudies aimed to clarify the relationship between endocytoscopic findings of gastrointestinal neoplasia and pathological diagnosis. Some studies have investigated non-epithelial lesions or diseases, such as inflammatory bowel disease or infectious diseases. However, there are few high-level pieces of evidence, such as randomized trials; thus, further studies are needed.